Skip To Main Content
Minal Barve on Muck Rack

Minal Barve

As seen in: Nature, Wiley Online Library, The BMJ
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Minal

Contact Minal, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies

|
By Aung Naing, Anna Spreafico, Minal Barve
| The BMJ Verified
NKG2A is an immune inhibitory receptor expressed on natural killer cells and T cells. Cancer cells exploit the NKG2A inhibitory pathway, thereby protecting themselves against antitumor immunity. NKG2A targeting may contribute to anti-programmed cell death protein 1 immune checkpoint activity. Our first-in-human, phase 1 study of an anti-NKG2A antibody demonstrated a favorable safety profile and preliminary antitumor activity in unselected, heavily pretreated patients with advanced malignancies.
Open in Who Shared Issue with article?

SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial

|
By Herui Yao, Min Yan, Zhongsheng Tong, Xinhong Wu, Yongmei Yin, Min-Hee Ryu, John Park, Shusuan Jiang, Jee Hyun Kim, Shouman Wang, Yahua Zhong, Mark Voskoboynik, Jian Zhang, Andreas Kaubisch, Caigang Liu, Yu Chen, Seock-Ah Im, Lingying Wu, Yingbin Liu, Vinod Ganju, Minal Barve, Hui Li, Guangyu Yao, Lequn Bao, Yiming Zhao Verified, Jianli Zhao, Yu Shen, Xiaoyu Zhu, Erwei Song, Mudan Yang, Kaijing Zhao, Shangyi Rong
| Nature Verified
Abstract SHR-A1811, an antibody‒drug conjugate consisting of the anti-HER2 antibody trastuzumab conjugated via a cleavable linker to a topoisomerase I inhibitor payload, demonstrated substantial antitumor activity in patients with heavily treated HER2-expressing or mutated advanced solid tumors. The main analysis was reported, and this is a long-term follow-up of the HORIZON-X trial (NCT04446260).
Open in Who Shared Issue with article?

Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer

|
By Oladapo O. Yeku, Minal Barve, Winston Tan, Judy Wang
| The BMJ Verified
Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Open in Who Shared Issue with article?
See all 6 articles